215 related articles for article (PubMed ID: 37373427)
1. NOTCH Signaling in Mantle Cell Lymphoma: Biological and Clinical Implications.
Deshotels L; Safa FM; Saba NS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373427
[TBL] [Abstract][Full Text] [Related]
2. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
3. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.
Silkenstedt E; Arenas F; Colom-Sanmartí B; Xargay-Torrent S; Higashi M; Giró A; Rodriguez V; Fuentes P; Aulitzky WE; van der Kuip H; Beà S; Toribio ML; Campo E; López-Guerra M; Colomer D
J Exp Clin Cancer Res; 2019 Nov; 38(1):446. PubMed ID: 31676012
[TBL] [Abstract][Full Text] [Related]
4. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.
Kridel R; Meissner B; Rogic S; Boyle M; Telenius A; Woolcock B; Gunawardana J; Jenkins CE; Cochrane C; Ben-Neriah S; Tan K; Morin RD; Opat S; Sehn LH; Connors JM; Marra MA; Weng AP; Steidl C; Gascoyne RD
Blood; 2012 Mar; 119(9):1963-71. PubMed ID: 22210878
[TBL] [Abstract][Full Text] [Related]
5. Do mantle cell lymphomas have an 'Achilles heel'?
Saba N; Wiestner A
Curr Opin Hematol; 2014 Jul; 21(4):350-7. PubMed ID: 24857884
[TBL] [Abstract][Full Text] [Related]
6. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.
Beà S; Valdés-Mas R; Navarro A; Salaverria I; Martín-Garcia D; Jares P; Giné E; Pinyol M; Royo C; Nadeu F; Conde L; Juan M; Clot G; Vizán P; Di Croce L; Puente DA; López-Guerra M; Moros A; Roue G; Aymerich M; Villamor N; Colomo L; Martínez A; Valera A; Martín-Subero JI; Amador V; Hernández L; Rozman M; Enjuanes A; Forcada P; Muntañola A; Hartmann EM; Calasanz MJ; Rosenwald A; Ott G; Hernández-Rivas JM; Klapper W; Siebert R; Wiestner A; Wilson WH; Colomer D; López-Guillermo A; López-Otín C; Puente XS; Campo E
Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18250-5. PubMed ID: 24145436
[TBL] [Abstract][Full Text] [Related]
7. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
[TBL] [Abstract][Full Text] [Related]
8. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades.
Swerdlow SH; Williams ME
Hum Pathol; 2002 Jan; 33(1):7-20. PubMed ID: 11823969
[TBL] [Abstract][Full Text] [Related]
9. TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.
Kim DH; Siddiqui S; Jain P; Wang M; Thakral B; Li S; Miranda R; Vega F; Medeiros LJ; Ok CY
Hum Pathol; 2024 Apr; 146():1-7. PubMed ID: 38460798
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
[TBL] [Abstract][Full Text] [Related]
11. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
[TBL] [Abstract][Full Text] [Related]
12. Characterization of 4 mantle cell lymphoma cell lines.
Amin HM; McDonnell TJ; Medeiros LJ; Rassidakis GZ; Leventaki V; O'Connor SL; Keating MJ; Lai R
Arch Pathol Lab Med; 2003 Apr; 127(4):424-31. PubMed ID: 12683869
[TBL] [Abstract][Full Text] [Related]
13. CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma.
Miao Y; Lin P; Wang W; Jeffrey Medeiros L; Lu X
Am J Clin Pathol; 2016 Dec; 146(6):747-752. PubMed ID: 28028120
[TBL] [Abstract][Full Text] [Related]
14. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.
Meissner B; Kridel R; Lim RS; Rogic S; Tse K; Scott DW; Moore R; Mungall AJ; Marra MA; Connors JM; Steidl C; Gascoyne RD
Blood; 2013 Apr; 121(16):3161-4. PubMed ID: 23407552
[TBL] [Abstract][Full Text] [Related]
15. An Uncommon Case of Double-Hit Mantle Cell Lymphoma That Demonstrates a Transformation Process.
Zhou J; Hu L; Zuo M; Zhou Y; Li G; Zhang X
Am J Clin Pathol; 2020 Jan; 153(1):49-57. PubMed ID: 31433838
[TBL] [Abstract][Full Text] [Related]
16. Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China.
Yang P; Liu SZ; Li CY; Zhang WL; Wang J; Chen YT; Li S; Liu CL; Liu H; Cai QQ; Zhang W; Jing HM
Ann Hematol; 2024 Jan; ():. PubMed ID: 38165416
[TBL] [Abstract][Full Text] [Related]
17. MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma.
Choe JY; Yun JY; Na HY; Huh J; Shin SJ; Kim HJ; Paik JH; Kim YA; Nam SJ; Jeon YK; Park G; Kim JE
Histopathology; 2016 Feb; 68(3):442-9. PubMed ID: 26100211
[TBL] [Abstract][Full Text] [Related]
18. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
Hill HA; Qi X; Jain P; Nomie K; Wang Y; Zhou S; Wang ML
Blood Adv; 2020 Jul; 4(13):2927-2938. PubMed ID: 32598477
[TBL] [Abstract][Full Text] [Related]
19. The pathologic diagnosis of mantle cell lymphoma.
Li S; Xu J; You MJ
Histol Histopathol; 2021 Oct; 36(10):1037-1051. PubMed ID: 34114641
[TBL] [Abstract][Full Text] [Related]
20. Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.
Aukema SM; Croci GA; Bens S; Oehl-Huber K; Wagener R; Ott G; Rosenwald A; Kluin PM; van den Berg E; Bosga-Bouwer AG; Hoogendoorn M; Hoster E; Bittmann I; Nagel I; Murga Penas EM; Kreuz M; Bausinger J; Belder W; Oschlies I; Dyer MJS; Jayne S; Siebert R; Klapper W
Virchows Arch; 2021 Jul; 479(1):133-145. PubMed ID: 33528622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]